We next titrated two commercially available α4β7 mAbs, Act1 (specific for the α4β7 heterodimer) and 2B4 (specific for α4), both of which have been shown to inhibit gp120 binding and to suppress infection of atRA-treated CD4+ T cells by the laboratory adapted HIV-1/SF162 strain, using concentrations previously reported to be saturating for Act1 [33]. The gene discussed is ITIH4; the disease is infection.